SCHEMBL13533461

SCHEMBL13533461

CNc1nc2ccccc2c2c1ncn2Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 10/20 0.60
ADORA2A P29274 2/20 0.53
PDE4D Q08499 3/20 0.49
PDE4A P27815 2/20 0.49
PDE4B Q07343 2/20 0.49
PDE4C Q08493 2/20 0.49
IKBKB O14920 1/20 0.48
CHUK O15111 1/20 0.48
TLR7 Q9NYK1 2/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
HRH2 P25021 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR2A P28223 1/20 0.47
ADRA1A P35348 1/20 0.47
NUDT1 P36639 1/20 0.47
HTR2B P41595 1/20 0.47
KCNH2 Q12809 1/20 0.47
TNF P01375 1/20 0.46
CYP11B1 P15538 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13533458 0.83 TLR7 (0.69) YTHDC1ADORA2APDE4DPDE4APDE4B
SCHEMBL13533465 0.83 IKBKB (0.50) YTHDC1ADORA2APDE4DPDE4APDE4B
SCHEMBL13533460 0.82 IKBKB (0.49) YTHDC1ADORA2APDE4DPDE4APDE4B
SCHEMBL14537690 0.81 ADORA3 (0.44) YTHDC1ADORA2APDE4DPDE4APDE4B
SCHEMBL9601993 0.81 CYP11B1 (0.50) YTHDC1ADORA2APDE4DPDE4ATLR7
SCHEMBL13533472 0.80 IKBKB (0.47) YTHDC1ADORA2APDE4DPDE4APDE4B
SCHEMBL13533468 0.80 IKBKB (0.47) YTHDC1ADORA2APDE4DPDE4APDE4B
SCHEMBL3188618 0.80 TLR7 (0.67) ADORA2APDE4DPDE4APDE4BPDE4C
SCHEMBL9199346 0.80 CYP11B1 (0.53) ADORA2APDE4DPDE4ATLR7LMNA
SCHEMBL9602894 0.79 TLR7 (0.51) YTHDC1ADORA2APDE4DIKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567329-B2 High penetration prodrug compositions of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds and uses thereof TECHFIELDS PHARMA CO., LTD. (CN) 2017-02-14 US disclosed
US-9567329-B2 High penetration prodrug compositions of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds and uses thereof TECHFIELDS PHARMA CO., LTD. (CN) 2017-02-14 US disclosed
US-20130131100-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF PREMIER RESEARCH INTERNATIONAL, LLC 2013-05-23 US disclosed
US-20130131100-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF PREMIER RESEARCH INTERNATIONAL, LLC 2013-05-23 US disclosed
US-8349866-B2 High penetration prodrug compositions of 1H-imidazo[4,5-C]quinolin-4-amines and 1H-imidazo[4,5-C]quinolin-4-amine-related compounds PREMIER RESEARCH INTERNATIONAL, LLC 2013-01-08 US disclosed
US-8349866-B2 High penetration prodrug compositions of 1H-imidazo[4,5-C]quinolin-4-amines and 1H-imidazo[4,5-C]quinolin-4-amine-related compounds PREMIER RESEARCH INTERNATIONAL, LLC 2013-01-08 US disclosed
US-20100021394-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS PREMIER RESEARCH INTERNATIONAL, LLC 2010-01-28 US disclosed
US-20100021394-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS PREMIER RESEARCH INTERNATIONAL, LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131100-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF HRH4, SLC7A1, ABCG2 YTHDC1 3095/4885ADORA2A 354/4885PDE4D 747/4885
US-20100021394-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS SLC7A1, HRH4, CYP3A4 YTHDC1 2873/4885ADORA2A 382/4885PDE4D 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.